Opinion|Videos|April 1, 2026
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Author(s)Christine M. Lovly, MD, PhD, Matthew Lee, MD
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss second-line treatment approaches and sequencing considerations in EGFR-mutated non–small cell lung cancer.
Advertisement
Episodes in this series
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss evolving strategies for second-line treatment in EGFR-mutated non–small cell lung cancer. Lovly reviews how resistance mechanisms and prior therapy exposure guide treatment selection, including the use of targeted agents and antibody-drug conjugates. Lee underscores the importance of integrating emerging data from phase 3 trials such as MARIPOSA-2 (NCT04988295) and PALOMA-3 (NCT05388669) to refine sequencing decisions.
Advertisement
Related to this article
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
Roswell Park Comprehensive Cancer Center received a grant to advance CAR T-cell therapy research in pediatric AML.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
Safusidenib produced a 51.9% confirmed ORR and a 79.1% 36-month PFS rate in chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
4
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
5